IP Library › Granted Patent US 12,589,101
Granted Patent B2
US 12,589,101 · App. 17/837,598 · Granted Mar 31, 2026

Cyclodextrin protein drug conjugates

Inventors: Amy Han (Hockessin, DE); William Olson (Yorktown Heights, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
A61K31/573A61K31/724A61K47/61A61K47/6803A61K47/68031A61K47/6807A61K47/6817A61K47/6849A61K47/6851A61K47/6889A61P3/00A61P25/00A61P29/00A61P35/00A61P35/04C07J43/003C07J71/0031
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,589,101
App. No.
17/837,598
Granted
Mar 31, 2026
Kind
B2
Abstract

Provided herein are compounds, compositions, conjugates and methods for the treatment of diseases, and/or conditions such as, but not limited to, proliferative diseases. In certain embodiments, compounds, compositions, and conjugates are provided, which include cyclodextrin-based linker-payloads and protein conjugates thereof, and/or in combination with other agents. By administering these compounds, compositions, and conjugates as described herein to specific target cells, side-effects due to non-specific binding phenomena, for example, to non-target cells are reduced.

Claims (126)

1 . A method for the treatment of a disease or disorder in a patient in need thereof comprising administering a compound or a pharmaceutically acceptable salt thereof to the patient, wherein the disease or disorder is selected from the group consisting of a proliferative disorder, a neurodegenerative disorder, an immunological disorder, an autoimmune disease, an inflammatory disorder, a dermatological disease, a metabolic disease, a cardiovascular disease, and a gastrointestinal disease, and wherein the compound is according to:

(i) Formula (Ib1), Formula (Ib2), or Formula (Ic1):

(ii) a Formula selected from the group consisting of:

wherein BA is an antibody or an antigen binding fragment thereof;

LL is a trivalent linker;

SP is, independently in each instance, absent or is a spacer;

n is an integer from 1 to 30; and

PA is a payload moiety; or

a regioisomer and/or stereoisomer thereof;

(iii) Formula (Id):

wherein:

BA is an antibody or antigen binding fragment thereof;

RG is a reactive group residue independently selected from the group consisting of

wherein the

indicates the atom through which the RG is bonded to the adjacent groups in the formula;

SP 1 and SP 2 are each, independently in each instance, a spacer group residue, and wherein SP 1 comprises a trivalent linker when attached to -CD, or SP 1 -CD or SP 2 are independently, in each instance, absent;

AA 1 is a trivalent linker comprising an amino acid residue;

AA 2 is a di-peptide residue;

PEG is a polyethylene glycol residue;

PAB is

wherein the

indicates the atom through which the PAB is bonded to the adjacent groups in the formula;

CD is, independently in each instance, absent, a cyclodextrin, or a modified cyclodextrin wherein the modified cyclodextrin is -SP 3 -RG-cyclodextrin; and, wherein at least one of CD is present;

SP 3 is, independently in each instance, absent or a spacer group residue;

cyclodextrin is selected from the group consisting of

wherein the

indicates the atom through which the cyclodextrin is bonded to the adjacent groups in the formula;

subscript n is an integer from 1 to 30;

subscript m is an integer from 0 to 5;

subscript p is 0 or 1; and

PA is a payload moiety; or

a regioisomer and/or stereoisomer thereof; or

(iv) Formula (Ie):

wherein:

BA is an antibody or antigen binding fragment thereof;

RG is, independently in each instance, a reactive group residue;

SP 2 is, independently in each instance, absent or a spacer group residue;

AA 1 is a trivalent linker comprising an amino acid residue;

AA 2 is a di-peptide residue;

PEG is a polyethylene glycol residue;

PAB is

wherein the

indicates the atom through which the PAB is bonded to the adjacent groups in the formula;

CD is a cyclodextrin residue;

subscript n is an integer from 1 to 30;

subscript m is an integer from 0 to 5;

subscript p is 0 or 1; and

PA is a payload moiety; or

a regioisomer and/or stereoisomer thereof.

2 . The method of claim 1 , wherein the compound is according to Formula (Ib1) or Formula (Ib2):

or a regioisomer and/or stereoisomer thereof.

3 . The method of claim 1 , wherein the compound is according to Formula (Ib3), Formula (Ib4), Formula (Ib5), or Formula (Ib6):

or a regioisomer and/or stereoisomer thereof.

4 . The method of claim 1 , wherein the compound is according to Formula (Ic1):

or a regioisomer and/or stereoisomer thereof.

5 . The method of claim 1 , wherein the compound is according to Formula (Id):

or a regioisomer and/or stereoisomer thereof.

6 . The method of claim 1 , wherein the compound is according to Formula (Ie):

or a regioisomer and/or stereoisomer thereof.

7 . The method of claim 6 , wherein the compound is according to Formula (Ie1):

or a regioisomer and/or stereoisomer thereof.

8 . The method of claim 7 , wherein the compound is according to Formula (Ie2):

or a regioisomer and/or stereoisomer thereof.

9 . The method of claim 1 , wherein the compound is according to Formula (If):

or a regioisomer and/or stereoisomer thereof;

wherein subscript q is an integer from 0 to 5.

10 . The method of claim 1 , wherein CD is, independently in each instance, selected from the group consisting of:

wherein the

indicates the atom through which the CD is bonded to the adjacent groups in the formula.

11 . The method of claim 1 , wherein CD is, independently in each instance, selected from the group consisting of:

wherein the

indicates the atom through which the CD is bonded to the adjacent groups in the formula.

12 . The method of claim 1 , wherein CD is, independently in each instance, selected from the group consisting of:

wherein the

indicates the atom through which the CD is bonded to the adjacent groups in the formula.

13 . The method of claim 1 , wherein RG is, independently in each instance, a click chemistry residue.

14 . The method of claim 1 , wherein RG, independently in each instance, comprises a triazole or a fused triazole.

15 . The method of claim 1 , wherein RG is, independently in each instance, selected from the group consisting of

wherein the

indicates the atom through which the RG is bonded to the adjacent groups in the formula.

16 . The method of claim 5 , wherein the compound according to Formula (Id):

is selected from the group consisting of

or a pharmaceutically acceptable salt, or stereoisomeric form thereof, or a regioisomer thereof, or mixture of regioisomers thereof, wherein:

each

is a bond to the antibody or an antigen binding fragment thereof;

each

is a bond to the payload moiety; and

R 9 is —CH 3 or —(CH 2 ) 3 N(H)C(O)NH 2 .

17 . The method of claim 16 , wherein the compound according to Formula (Id):

is selected from the group consisting of

or a pharmaceutically acceptable salt, or stereoisomeric form thereof, or a regioisomer thereof, or mixture of regioisomers thereof, wherein:

each

is a bond to the antibody or an antigen binding fragment thereof; and

each

is a bond to the payload moiety.

18 . The method of claim 1 , wherein -LL- is according to the Formula (LL1):

wherein R AA1 , R AA2 , and R AA3 are each, independently, amino acid side chains, at least one of which is bonded directly or indirectly to CD.

19 . The method of claim 18 , wherein R AA1 is a lysine side chain bonded directly or indirectly to CD and R AA2 and R AA3 taken together, are either valine and citrulline or valine and alanine side chains, respectively.

20 . The method of claim 18 , wherein R AA2 and R AA3 , taken together, are:

21 . The method of claim 1 , wherein the spacer group is, independently in each instance, selected from the group consisting of C 1-6 alkylene, —NH—, —C(O)—, (—CH 2 —CH 2 —O) e, —NHCH 2 —CH 2 —(—O—CH 2 —CH 2 )e-C(O)—, —C(O)—(CH 2 )u-C(O)—, —C(O)—NH—(CH 2 )v-, and combinations thereof, wherein subscript e is an integer from 0 to 4, subscript u is an integer from 1 to 8, and subscript v is an integer from 1 to 8.

22 . The method of claim 21 , wherein e is 4.

23 . The method of claim 22 , wherein subscript p is 1.

24 . The method of claim 1 , wherein subscript n is 2-4.

25 . The method of claim 1 , wherein the antibody or antigen-binding fragment thereof is selective for an antigen selected from the group consisting of AXL, BAFFR, BCMA, BCR-list components, BDCA2, BDCA4, BTLA, BTNL2, BTNL3, BTNL8, BTNL9, C10 or f54, CCR1, CCR3, CCR4, CCR5, CCR6, CCR7, CCR9, CCR10, CD11c, CD137, CD138, CD14, CD168, CD177, CD19, CD20, CD209, CD209L, CD22, CD226, CD248, CD25, CD27, CD274, CD276, CD28, CD30, CD300A, CD33, CD37, CD38, CD4, CD40, CD44, CD45, CD46, CD48, CDS, CD52, CD55, CD56, CD59, CD62E, CD68, CD69, CD70, CD74, CD79a, CD79b, CD8, CD80, CD86, CD90.2, CD96, CLEC12A, CLEC12B, CLEC7A, CLEC9A, CR1, CR3, CRTAM, CSF1R, CTLA4, CXCR1/2, CXCR4, CXCR5, DDR1, DDR2, DEC-205, DLL4, DR6, FAP, FCamR, FCMR, FeR′s, Fire, GITR, HHLA2, HLA class II, HVEM, ICOSLG, IFNLR1, IL10R1, IL10R2, IL12R, IL13RA1, IL13RA2, IL15R, IL17RA, IL17RB, IL17RC, IL17RE, IL20R1, IL20R2, IL21R, IL22R1, IL22RA, IL23R, IL27R, IL29R, IL2Rg, IL31R, IL36R, IL3RA, IL4R, IL6R, ILSR, IL7R, IL9R, Integrins, LAG3, LIFR, MAG/Siglec-4, MMR, MSR1, NCR3LG1, NKG2D, NKp30, NKp46, PDCD1, PROKR1, PVR, PVRIG, PVRL2, PVRL3, RELT, SIGIRR, Siglec-1, Siglec-10, Siglec-5, Siglec-6, Siglec-7, Siglec-8, Siglec-9, SIRPA, SLAMF7, TACI, TCR-list components/assoc, PTCRA, TCRb, CD3z, CD3, TEK, TGFBR1, TGFBR2, TGFBR3, TIGIT, TLR2, TLR4, TROY, TSLPR, TYRO, VLDLR, VSIG4, and VTCN1.

26 . The method of claim 1 , wherein the antibody or the antigen-binding fragment thereof is coupled to a primary amine compound by a transglutaminase-mediated coupling.

27 . The method of claim 26 , wherein the glutaminyl-modified antibody is an antibody modified with an azido-polyethylene glycol compound.

28 . The method of claim 1 , wherein the antibody is conjugated to a reactive group compound at a glutamine residue, and LL is bonded to BA through said reactive group compound.

29 . The method of claim 28 , wherein the reactive group compound comprises a divalent polyethylene glycol group.

30 . The method of claim 1 , wherein PA is a residue of a group selected from the group consisting of a dolastatin, an auristatin, a maytansinoid, a taxane, a vinca alkaloid, a steroid, an LXR modulator, a pyrrolobenzodiazepine, a tubulysin, and a camptothecin.

31 . The method of claim 30 , wherein PA is selected from the group consisting of

wherein the

indicates the atom through which the PA is bonded to the adjacent groups in the formula.

32 . The method of claim 30 , wherein PA is a residue of a maytansinoid, steroid, LXR modulator, pyrrolobenzodiezepine, tubulysirr, or camptothecin.

33 . The method of claim 32 , wherein PA is a residue of an auristatin.

34 . The method of claim 32 , wherein PA is a residue of a maytansinoid.

35 . The method of claim 32 , wherein PA is a residue of a glucocorticoid.

36 . The method of claim 32 , wherein PA is a residue of a liver X receptor modulator.

37 . The method of claim 17 , wherein the compound is selected from the group consisting of:

or a stereoisomeric form, or a pharmaceutically acceptable salt thereof, or a regioisomer thereof, or mixture of regioisomers thereof; wherein Ab is an antibody or antigen-binding fragment thereof;

PA is a payload moiety; and

n is an integer from 1 to 30.

38 . The method of claim 17 , wherein the compound is selected from the group consisting of:

or a stereoisomeric form, or a pharmaceutically acceptable salt thereof, or a regioisomer thereof, or mixture of regioisomers thereof; wherein Ab is an antibody or antigen-binding fragment thereof; and n is an integer from 1 to 30.

39 . The method of claim 1 , wherein the disease or disorder is a proliferative disorder.

40 . The method of claim 1 , wherein the disease or disorder is an inflammatory disorder.

41 . The method of claim 1 , wherein the disease or disorder is a metabolic disease.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2025
From: HAN, AMY; OLSON, WILLIAM
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 071236/0708 →
Continuity (3)
Division 15975191 · May 9, 2018
Provisional Application 62508315 · May 18, 2017
Related Publication 20230035898A1 · Feb 2, 2023
References Cited (313)
US 2920999A · Agnello et al. · 1960 [cited by applicant]
US 3007923A · Muller et al. · 1961 [cited by applicant]
US 3020275A · Marx et al. · 1962 [cited by applicant]
US 3033873A · Pinson et al. · 1962 [cited by applicant]
US 3033874A · Pinson et al. · 1962 [cited by applicant]
US 3047468A · Origoni et al. · 1962 [cited by applicant]
US 3197469A · Fried · 1965 [cited by applicant]
US 3232839A · Kieslich et al. · 1966 [cited by applicant]
US 3383394A · Weber et al. · 1968 [cited by applicant]
US 3723484A · Laurant et al. · 1973 [cited by applicant]
US 3798216A · Boissier et al. · 1974 [cited by applicant]
US 3886145A · Diamanti · 1975 [cited by applicant]
US 3928326A · Brattsand et al. · 1975 [cited by applicant]
US 3929768A · Brattsand et al. · 1975 [cited by applicant]
US 4076737A · Anner et al. · 1978 [cited by applicant]
US 4925933A · Jakupovic et al. · 1990 [cited by applicant]
US 5116829A · Hori et al. · 1992 [cited by applicant]
US 5183815A · Saari et al. · 1993 [cited by applicant]
US 5208020A · Chari et al. · 1993 [cited by applicant]
US 5500362A · Robinson et al. · 1996 [cited by applicant]
US 5714586A · Kunstmann et al. · 1998 [cited by applicant]
US 5821337A · Carter et al. · 1998 [cited by applicant]
US 5837698A · Tjoeng et al. · 1998 [cited by applicant]
US 5908833A · Brattsand et al. · 1999 [cited by applicant]
US 6596541B2 · Murphy et al. · 2003 [cited by applicant]
US 6908934B2 · Adams et al. · 2005 [cited by applicant]
US 7750116B1 · Doronina et al. · 2010 [cited by applicant]
US 8524697B2 · Anthes et al. · 2013 [cited by applicant]
US 8703714B2 · Doronina et al. · 2014 [cited by applicant]
US 9375473B2 · Latov et al. · 2016 [cited by applicant]
US 10711032B2 · Han et al. · 2020 [cited by applicant]
US 11129903B2 · Andreev et al. · 2021 [cited by applicant]
US 11491237B2 · Han et al. · 2022 [cited by applicant]
US 11578135B2 · Papadopoulos et al. · 2023 [cited by applicant]
US 11760775B2 · Han et al. · 2023 [cited by applicant]
US 12070506B2 · Han et al. · 2024 [cited by applicant]
US 20030125357A1 · Adams et al. · 2003 [cited by applicant]
US 20030199529A1 · Garvey et al. · 2003 [cited by applicant]
US 20040077595A1 · Cheng et al. · 2004 [cited by applicant]
US 20040157810A1 · Teicher et al. · 2004 [cited by applicant]
US 20040192778A1 · Jardien et al. · 2004 [cited by applicant]
US 20050009798A1 · Currie et al. · 2005 [cited by applicant]
US 20050192257A1 · Peyman · 2005 [cited by applicant]
US 20050287155A1 · Santi et al. · 2005 [cited by applicant]
US 20060046967A1 · Satyam · 2006 [cited by applicant]
US 20060074008A1 · Senter et al. · 2006 [cited by applicant]
US 20070258987A1 · Francisco et al. · 2007 [cited by applicant]
US 20080171040A1 · Ebens et al. · 2008 [cited by applicant]
US 20080305044A1 · McDonagh et al. · 2008 [cited by applicant]
US 20080305497A1 · Kosmeder et al. · 2008 [cited by applicant]
US 20090221543A1 · Soldato et al. · 2009 [cited by applicant]
US 20090318396A1 · Baker et al. · 2009 [cited by applicant]
US 20100041633A1 · Benedini et al. · 2010 [cited by applicant]
US 20100093685A1 · Benedini et al. · 2010 [cited by applicant]
US 20100129314A1 · Singh et al. · 2010 [cited by applicant]
US 20100209508A1 · Baker et al. · 2010 [cited by applicant]
US 20100226987A1 · Gnaim et al. · 2010 [cited by applicant]
US 20100323973A1 · Leamon et al. · 2010 [cited by applicant]
US 20110178287A1 · Glucksmann et al. · 2011 [cited by applicant]
US 20110182828A1 · Anthes et al. · 2011 [cited by applicant]
US 20110262368A1 · Anthes et al. · 2011 [cited by applicant]
US 20120058892A1 · Braun et al. · 2012 [cited by applicant]
US 20120059158A1 · Ishii · 2012 [cited by applicant]
US 20120096572A1 · Macdonald et al. · 2012 [cited by applicant]
US 20120258107A1 · Graversen et al. · 2012 [cited by applicant]
US 20120276193A1 · Graversen et al. · 2012 [cited by applicant]
US 20120302505A1 · Fetzer · 2012 [cited by examiner]
US 20130101546A1 · Yurkovetskiy et al. · 2013 [cited by applicant]
US 20140227294A1 · Anderson et al. · 2014 [cited by applicant]
US 20150152187A1 · Sun et al. · 2015 [cited by applicant]
US 20150165064A1 · Bregeon et al. · 2015 [cited by applicant]
US 20150258203A1 · Vlahov et al. · 2015 [cited by applicant]
US 20150290337A1 · Vetter et al. · 2015 [cited by applicant]
US 20150291563A1 · Park et al. · 2015 [cited by applicant]
US 20160082119A1 · Gonzalez et al. · 2016 [cited by applicant]
US 20160158369A1 · Sato et al. · 2016 [cited by applicant]
US 20160279054A1 · Rangaramanujam et al. · 2016 [cited by applicant]
US 20160310612A1 · Lyon et al. · 2016 [cited by applicant]
US 20160340445A1 · Bouckaert et al. · 2016 [cited by applicant]
US 20170182181A1 · Garbaccio et al. · 2017 [cited by applicant]
US 20180002372A1 · Tripathi et al. · 2018 [cited by applicant]
US 20180126000A1 · Mcpherson et al. · 2018 [cited by applicant]
US 20180155389A1 · Han et al. · 2018 [cited by applicant]
US 20180334426A1 · Han et al. · 2018 [cited by applicant]
US 20180360979A1 · Mejia Oneto et al. · 2018 [cited by applicant]
US 20190030171A1 · Garbaccio et al. · 2019 [cited by applicant]
US 20190134220A1 · Godwin · 2019 [cited by applicant]
US 20190167804A1 · Hobson et al. · 2019 [cited by applicant]
US 20190209702A1 · Han · 2019 [cited by applicant]
US 20190367631A1 · Gromada · 2019 [cited by examiner]
US 20200115326A1 · Tsuchikama et al. · 2020 [cited by applicant]
US 20200368361A1 · Nittoli et al. · 2020 [cited by applicant]
US 20210040144A1 · Han et al. · 2021 [cited by applicant]
US 20220080052A1 · Gromada et al. · 2022 [cited by applicant]
US 20230079407A1 · Gromada et al. · 2023 [cited by applicant]
US 20230119539A1 · Han · 2023 [cited by applicant]
AU 2018270784A1 · 2019 [cited by applicant]
CN 1414008A · 2003 [cited by applicant]
CN 101397328A · 2009 [cited by applicant]
CN 103694375A · 2014 [cited by applicant]
CN 104302664A · 2015 [cited by applicant]
CN 107849131A · 2018 [cited by applicant]
CN 108853514A · 2018 [cited by applicant]
CN 109106951A · 2019 [cited by applicant]
DE 1165595B · 1964 [cited by applicant]
EP 1625854A1 · 2006 [cited by applicant]
ES 544825A1 · 1985 [cited by applicant]
GB 889766A · 1962 [cited by applicant]
GB 898295A · 1962 [cited by applicant]
GB 1428416 · 1976 [cited by applicant]
IL 73337A · 1988 [cited by applicant]
JP 7617974B2 · 2025 [cited by applicant]
KR 20250008984A · 2025 [cited by applicant]
WO WO9422898A1 · 1994 [cited by applicant]
WO WO2000049993A2 · 2000 [cited by applicant]
WO WO2002080931A1 · 2002 [cited by applicant]
WO WO2004017904A2 · 2004 [cited by applicant]
WO WO2004022099A2 · 2004 [cited by applicant]
WO WO2005063777A1 · 2005 [cited by applicant]
WO WO2005079523A2 · 2005 [cited by applicant]
WO WO2005089808 · 2005 [cited by applicant]
WO WO2005119266A1 · 2005 [cited by applicant]
WO WO2006135371A1 · 2006 [cited by applicant]
WO WO2008122039A2 · 2008 [cited by applicant]
WO WO2008127347A1 · 2008 [cited by applicant]
WO WO2009001364A2 · 2008 [cited by applicant]
WO WO2009085879A2 · 2009 [cited by applicant]
WO WO2009085880A2 · 2009 [cited by applicant]
WO WO2010010119A1 · 2010 [cited by applicant]
WO WO2010010324A1 · 2010 [cited by applicant]
WO WO2010126953A1 · 2010 [cited by applicant]
WO WO2010132743A1 · 2010 [cited by applicant]
WO WO2011018611A1 · 2011 [cited by applicant]
WO WO2011020107A2 · 2011 [cited by applicant]
WO WO2011039511A2 · 2011 [cited by applicant]
WO WO2011081937A1 · 2011 [cited by applicant]
WO WO2011103389A1 · 2011 [cited by applicant]
WO WO2011130598 · 2011 [cited by applicant]
WO WO2012011591A1 · 2012 [cited by applicant]
WO WO2012058592 · 2012 [cited by applicant]
WO WO2012145632 · 2012 [cited by applicant]
WO WO2012166559 · 2012 [cited by applicant]
WO WO2013053872 · 2013 [cited by applicant]
WO WO2013053873 · 2013 [cited by applicant]
WO WO2013055990 · 2013 [cited by applicant]
WO WO2013055993 · 2013 [cited by applicant]
WO WO2013068874 · 2013 [cited by applicant]
WO WO2013085925 · 2013 [cited by applicant]
WO WO2013093465A2 · 2013 [cited by applicant]
WO WO2014065661 · 2014 [cited by applicant]
WO WO2014165119 · 2014 [cited by applicant]
WO WO2014177771A1 · 2014 [cited by applicant]
WO WO2014197854 · 2014 [cited by applicant]
WO WO2015026907 · 2015 [cited by applicant]
WO WO2015153401A1 · 2015 [cited by applicant]
WO WO2015155998A1 · 2015 [cited by applicant]
WO WO2015189478A1 · 2015 [cited by applicant]
WO WO2016090038A1 · 2016 [cited by applicant]
WO WO2016090040A1 · 2016 [cited by applicant]
WO WO2016094509A1 · 2016 [cited by applicant]
WO WO2016094517A1 · 2016 [cited by applicant]
WO WO2016127081A1 · 2016 [cited by applicant]
WO WO2017006279A1 · 2017 [cited by applicant]
WO WO2017062271A1 · 2017 [cited by applicant]
WO WO2017132103A2 · 2017 [cited by applicant]
WO WO2017147542 · 2017 [cited by applicant]
WO WO2017165851A1 · 2017 [cited by applicant]
WO WO2017199046A1 · 2017 [cited by applicant]
WO WO2017210471A1 · 2017 [cited by applicant]
WO WO2017214458A2 · 2017 [cited by applicant]
WO WO2018058001 · 2018 [cited by applicant]
WO WO2018089373A2 · 2018 [cited by applicant]
WO WO2018160539A1 · 2018 [cited by applicant]
WO WO2018213077A1 · 2018 [cited by applicant]
WO WO2018213082A1 · 2018 [cited by applicant]
WO WO2019094395A2 · 2019 [cited by applicant]
WO WO2019136487A2 · 2019 [cited by applicant]
WO WO2019195665A1 · 2019 [cited by applicant]
WO WO2020146541A2 · 2020 [cited by applicant]
Patani et al., “Bioisosterism: A Rational Approach in Drug Design”, Chem. Rev. 96, 1996, pp. 3147-3176. [cited by applicant]
Thalen et al., “6a-Fluoro- and 6a,9a-difluoro-11b,21-dihydroxy-16a,17a-propylmethylenedioxypregn-4-ene-3,20-dione: Synthesis and evaluation of activity and kinetics of their C-22 epimers”, Steroids 63:37-43, 1998. [cited by applicant]
Gonzales et al., “Minimizing the Immunogenicity of Antibodies for Clinical Application”, Tumor Biol. 2005; vol. 26, pp. 31-43; doi: 10.1159/000084184. [cited by applicant]
Kunik, Vered et al: “Structural consensus among antibodies defines the antigen binding site”, PLoS Comput Biol 8(2): e1002388. https://doi.org/10.1371/journal.pcbi.1002388; Published Feb. 23, 2012. [cited by applicant]
Kussie et al., “A Single Engineered Amino Acid Substitution Changes Antibody Fine Specificity”, Journal of Immunology, 1994, pp. 146-152. [cited by applicant]
Opalinski et al., “High Affinity Promotes Internalization of Engineered Antibodies Targeting FGFR1”, International Journal of Molecular Sciences, 2018, vol. 19, 1435; Published online May 10, 2018. doi: 10.3390/ijms1905… [cited by applicant]
Panka et al., “Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies”, Proc. Natl. Acad. Scl. USA, vol. 85, May 1988, pp. 3080-30844, Immunology; doi: 10.1073… [cited by applicant]
Rudikoff, Stuart el al., “Single amino acid substitution altering antigen-binding specificity”, Proc. Nat. Acad. Sci., USA, vol. 79, Mar. 1982, pp. 1979-1983; DOI: 10.1073/pnas.79.6.1979. [cited by applicant]
Sela-Culang et al., “The Structural Basis of Antibody-Antigen Recognition”, Frontiers in Immunology, vol. 4, article 302, Oct. 2013; doi: 10.3389/fimmu.2013.00302. [cited by applicant]
Wark et al., “Latest technologies for the enhancement of antibody affinity”, Advanced Drug Delivery Reviews, 2006, vol. 58, pp. 657-670; doi:10.1016/j.addr.2006.01.025. [cited by applicant]
Besret et al., “Thiocarbamate-Linked Polysulfonate-Peptide Conjugates as Selective Hepatocyte Growth Factor Receptor Binders”, dx.doi.org/10.1021/bc500137j | Bioconjugate Chem. 2014, 25, pp. 1000-1010. [cited by applicant]
Reyna et al., “Targeted Delivery of LXR Agonist Using a Site-Specific Antibody-Drug Conjugate”, Bioconjugate Chem. 2015, 26, pp. 2216-2222; DOI: 10.1021/acs.bioconjchem.5b00203. [cited by applicant]
Millan et al., “Design and synthesis of long acting inhaled corticosteroids for the treatment of asthma”, Bioorganic & Medicinal Chemistry Letters 21 (2011) 5826-5830. [cited by applicant]
Makinen et al., “Silencing of either SR-A or CD36 reduces at herosclerosis in hyperlipidaemic mice and reveals reciprocal upregulation of these receptors”, Cardiovascular Research, 2010, vol. 88, No. 3, pp. 530-538. [cited by applicant]
Ozment et al., “Blood Monocyte Scavenger Receptor A (Cd204) Expression Is Increased in Septic Patients”, SHOCK, 2016, vol. 45, No. 6S, p. 129. [cited by applicant]
Bak et al., “Scavenger Receptor-A—Targeted Leukocyte Depletion Inhibits Peritoneal Ovarian Tumor Progression”, Cancer Res 2007; 67: (10). May 15, 2007; doi:10.1158/0008-5472.CAN-06-44-10. [cited by applicant]
CAS RN 91748-21-8 (entered into STN on 1/116/2007). [cited by applicant]
Mark Frigerio et al., “The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates”, Current Topics in Medicinal Chemistry, 2017, 17(32), pp. 3393-3424. [cited by applicant]
Everts et al., “Selective Intracellular Delivery of Dexamethasone into Activated Endothelial Cells Using an E-Selectin-Directed Immunoconjugate”, J Immunol (2002) 168 (2): 883-889; https://doi.org/10.4049/jimmunol.168.2… [cited by applicant]
Han et al., “Development of Novel Glucocorticoids for Use in Antibody-Drug Conjugates for the Treatment of Inflammatory Diseases”, J. Med. Chem. 2021, 64, pp. 11958-11971. [cited by applicant]
Pang et al., “Synthesis of an enzyme-dependent prodrug and evaluation of its potential for colon targeting”, World J Gastroenterol., Oct. 15, 2002; 8(5): 913-917; doi: 10.3748/wjg.v8.i5.913. [cited by applicant]
Varshosaz et al. “Synthesis and evaluation of dextran-budesonide conjugates as colon specific prodrugs for treatment of ulcerative colitis”, International Journal of Pharmaceutics, Jan. 5, 2009;365(1-2):69-76; doi:10.10… [cited by applicant]
International Search Report and the Written Opinion of PCT/US2018/031839 mailed Jul. 26, 2018; 20 pages. [cited by applicant]
Agard et al., “A Strain-Promoted [3+2] Azide-Alkyne Cycloaddition for Covalent Modification of Biomolecules in Living Systems”, J. Am. Chem. Soc., Nov. 24, 2004, vol. 126, No. 46, pp. 15046-15047. [cited by applicant]
Agarwal et al. (Bioconjugate Chem. 2015, 26, 176-192). [cited by applicant]
Agarwal et al., “A Pictet-Spengler ligation for protein chemical modification”, PNAS, Jan. 2, 2013, vol. 110, No. 1, pp. 46-51. [cited by applicant]
Aherne et al., “A sensitive radioimmunoassay for budesonide in plasma”, Journal of Steroid Biochemistry, vol. 17, No. 5, Nov. 1982, pp. 559-565. [cited by applicant]
Angal et al., “A Single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric Mouse/Human (lgG4) Antibody”, Molecular Immunology, Jan. 1993, vol. 30, No. 1, pp. 105-108. [cited by applicant]
Bajaj et al., “Topochemical model for prediction of anti-HIV activity of HEPT analogs”, Bioorganic & Medicinal Chemistry Letters, vol. 15, No. 2, Jan. 17, 2005, pp. 467-469. [cited by applicant]
Baskin et al., “Copper-free click chemistry for dynamic in vivo imaging”, PNAS, Oct. 23, 2007, vol. 104, No. 43, pp. 16793-16797. [cited by applicant]
Beck et al., “Strategies and challenges for the next generation of antibody-drug conjugates”, Nature Reviews/Drug Discovery, vol. 16, May 2017, pp. 315-337. [cited by applicant]
Berge et al., “Pharmaceutical Salts”, Review Article, Jan. 1977, vol. 66, No. 1, pp. 1-19. [cited by applicant]
Berlin M., “Recent advances in the development of novel glucocorticoid receptor modulators”, Review, Expert Opinion on Therapeutic Patents (2010) 20(7), pp. 855-873; DOI: 10.1517/13543776.2010.493876. [cited by applicant]
Biju et al., “Synthesis of novel anti-inflammatory steroidal macrocycles using ring closing metathesis reaction”, Tetrahedron Letters, Jan. 2015, vol. 56, issue 4, pp. 636-638. [cited by applicant]
Boersma et al., “DARPins and other repeat protein scaffolds: advances in engineering and applications”, 2011, Current Opinion in Biotechnology, 2011, vol. 22, pp. 849-857. [cited by applicant]
Bogan et al., “Liver X Receptor Modulation of Gene Expression Leading to Proluteolytic Effects in Primate Luteal Cells”, Biology Of Reproduction, (2012) 86(3):89, 1-9. [cited by applicant]
Cannon et al., “The liver X receptor agonist AZ876 protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects”, European Journal of Heart Failure, 2015, vol. 17, pp. 273-282. [cited by applicant]
Carrico et al., “Introducing genetically enclosed aldehydes into proteins”, Nature Chemical Biology, Jun. 2007, vol. 3, No. 6, pp. 321-322. [cited by applicant]
CAS Registry No. 803648-23-9; STN Entry Date Dec. 29, 2004; 21-(Diethylamino)-11,17-dihydroxy-(11β)-(9Cl)pregna-1,4-diene-3,20-dione [2] Category: X Claims: 1, 2, 4, 14; SciFinder [cited by applicant]
CAS Registry Compounds, accessed Jul. 16, 2019; 355 pages. [cited by applicant]
CAS RN 2341-08-4, 1984 (entered into STN Nov. 16, 1984). [cited by applicant]
CAS RN 3859-14-1, 1984 (entered into STN Nov. 16, 1984). [cited by applicant]
CAS RN 57-86-3, 1984 (entered into STN Nov. 16, 1984). [cited by applicant]
Casati et al., “Unraveling Unidirectional Threading of α-Cyclodextrin in a [2]Rotaxane through Spin Labeling Approach”, Journal of the American Chemical Society, Oct. 29, 2012, vol. 134, pp. 19108-19117. [cited by applicant]
Cho et al., “Regioselective Synthesis of Heterocycles Containing Nitrogen Neighboring an Aromatic Ring by Reductive Ring Expansion Using Diisobutylaluminum Hydride and Studies on the Reaction Mechanism”, J. Org. Chem., … [cited by applicant]
Cho et al., “The first preparation of alpha-functionalized benzylamine”, Tetrahedron Letters, vol. 40, No. 47, Nov. 19, 1999, p. 8215. [cited by applicant]
Chuu (Medical Hypotheses 76 (2011) 697-699). [cited by applicant]
Clynes et al., “Fc receptors are required in passive and active immunity to melanoma”, Proc. Natl. Acad. Sci. USA, Jan. 1998, vol. 95, pp. 652-656. [cited by applicant]
Compounds from CAS Registry database, accessed May 20, 2019; 16 pages. [cited by applicant]
Compounds retrieved on Nov. 18, 2017 from SciFinder, Set 1; 4 pages. [cited by applicant]
Compounds retrieved on Nov. 18, 2017 from SciFinder, Set 2; 1 page. [cited by applicant]
Compounds retrieved on Nov. 18, 2017 from SciFinder, Set 3; 3 pages. [cited by applicant]
Czerkies et al., “An interplay between scavenger receptor A and CD14 during activation of J774 cells by high concentrations of LPS”, Immunobiology, Apr. 12, 2013, vol. 218, pp. 1217-1226. [cited by applicant]
Dai et al., Regulation of MSR-1 and CD36 in macrophages by LOX-1 mediated through PPAR-c, Biochemical and Biophysical Research Communications, 431, pp. 496-500, Publication Date: Jan. 16, 2013. [cited by applicant]
Database Registry [Online] Chemical Abstracts Service Retrieved from STN on Aug. 11, 2020; Compounds with CAS Registry Numbers of 23640-98-4 (Entered STN: Nov. 16, 1984); 23640-97-3 (Entered STN: Nov. 16, 1984); 6477-56… [cited by applicant]
Database Registry: Compounds with CAS Registry No. of 23640-98-4; 23640-97-3; 6477-56-1; 5514-61-4; 2353-16-4. [cited by applicant]
Dennler et al. (Antibodies 2015, 4, 197-224). [cited by applicant]
Dennler et al., “Transglutaminase-Based Chemo-Enzymatic Conjugation Approach Yields Homogeneous Antibody-Drug Conjugates”, Bioconjugate Chem., Feb. 3, 2014, vol. 25, pp. 569-578. [cited by applicant]
Diamantis et al. (British Journal of Cancer (2016) 114, 362-367). [cited by applicant]
Doi et al., “The Histidine Interruption of An □-Helical Coiled Coil Allosterically Mediates A pH-Dependent Ligand Dissociation From Macrophage Scavenger Receptors”, The Journal of Biological Chemistry, vol. 269, No. 41,… [cited by applicant]
Doronina et al., “Novel Peptide Linkers for Highly Potent Antibody-Auristatin Conjugate”, Bioconjugate Chem., 2008, vol. 19, No. 10, pp. 1960-1963. [cited by applicant]
Doronina et al., “Development of potent monoclonal antibody auristatin conjugates for cancer therapy”, Nature Biotechnology, Jul. 2003, vol. 21, No. 7, pp. 778-941. [cited by applicant]
Dubois-Camacho et al., “Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology”, World J Gastroenterol, Sep. 28, 2017, vol. 23(36), pp. 6628-6638; DOI: 10.3748/wjg.v23.i3… [cited by applicant]
Effenberger et al., “Trifluormethansulfonate von [alpha]-Hydroxycarbonsaureestern—Edukte zur racemisierungsfreien Synthese N-substituierter [alpha]-Aminosauren”, Angewandte Chemie, vol. 95, No. 1, Jan. 1, 1983, p. 50. [cited by applicant]
Fellier et al., “Bindung von Cortisol, Fluocortolon und Difluocortolon a Humanplasmaproteine”, J. Clin. Chem. Clin. Biochem., 1977, vol. 15, pp. 545-548. [cited by applicant]
Ferraboschi et al., “Estimation and characterisation of budesonide tablets impurities”, Journal of Pharmaceutical and Biomedical Analysis, 2008, 47(3), pp. 636-640. [cited by applicant]
Friedman et al. (Curr Pharm Des. 2013; 19(35): 6315-6329). [cited by applicant]
Gidwani et al., “A Comprehensive Review on Cyclodextrin-Based Carriers for Delivery of Chemotherapeutic Cytotoxic Anticancer Drugs”, Hindawi Publishing Corporation, BioMed Research International, vol. 2015, article ID 1… [cited by applicant]
Graversen et al., “Targeting the Hemoglobin Scavenger receptor CD163 in Macrophages Highly Increases the Anti-inflammatory Potency of Dexamethasone”, Molecular Therapy, vol. 20, No. 8, Aug. 2012, pp. 1550-1558. [cited by applicant]
Hamasaki et al., “Fluorescent sensors of molecular recognition. Modified cyclodextrins capable of exhibiting guest-responsive twisted intramolecular charge transfer fluorescence”, J. Am. Chem. Soc., Jun. 1993, vol. 115,… [cited by applicant]
Hein et al., “The Synthesis of a Multiblock Osteotropic Polyrotaxane by Copper(I)-Catalyzed Huisgen 1,3-Dipolar Cycloaddition”, Macromolecular Bioscience, Dec. 8, 2010, vol. 10, No. 12, pp. 1544-1556, XP055052204. [cited by applicant]
Hofer et al., “An engineered selenocysteine defines a unique class of antibody derivatives”, PNAS, Aug. 26, 2008, vol. 105, No. 34, pp. 12451-12456. [cited by applicant]
Hollander et al., “Selection of Reaction Additives Used in the Preparetion of Monomeric Antibody-Calicheamicin Conjugates”, Bioconjugate Chem., 2008, vol. 19, pp. 358-361; published online Nov. 10, 2007. [cited by applicant]
Huisgen, “1,3-Dipolar Cycloadditions”, Proceedings of the Chemical Society, Oct. 1961, pp. 357-369. [cited by applicant]
Jain et al., “Current ADC Linker Chemistry”, Pharm Res, 2015, vol. 32, pp. 3526-3540; DOI 10.1007/s11095-015-1657-7. [cited by applicant]
Jain R. A., “The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices”, Biomaterials 21(23), 2000, pp. 2475-2490. [cited by applicant]
Jeger: “Site-specific conjugation of tumour-targeting, antibodies using transglutaminase”, Ph.D. thesis, 2009, XP055208841, ETH Zurich, CH; 140 pages. DOI: 10.3929/ethz-a-005963273; pp. 41-46. [cited by applicant]
Kapp et al., “Studies on the Pharmacology of 6alpha,9-difluoro-11beta-hydroxy-16alpha-methyl-21-valeryloxy-1,4-pregnadiene-3,20-dione”, Arzneimittel-Forschung Drug Reserch, 1976;26(7b):1463-1475; with an English summary. [cited by applicant]
Kern et al., “Discovery of Pyrophosphate Diesters as Tunable, Soluble, and Bioorthogonal Linkers for Site-Specific Antibody-Drug Conjugates”, J. Am. Chem. Soc. (JACS), Jan. 25, 2016, vol. 138, No. 4, pp. 1430-1445. [cited by applicant]
Kern et al., “Novel Phosphate Modified Cathepsin B Linkers: Improving Aqueous Solubility and Enhancing Payload Scope of ADCs”, Bioconjugate Chem. Bioconjugate Chem., Jul. 28, 2016, vol. 27, No. 9, pp. 2081-2088. [cited by applicant]
Kovtun et al., “Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance”, Cancer Research, vol. 70, No. 6, Mar. 15, 2010, pp. 2528-2537. [cited by applicant]
Krajcsi et al., “Novel Synthesis of 21-Aminopregnanes”, J. Chem. Research (S), Nov. 1987, issue 11, pp. 382-383. [cited by applicant]
Kronkvist et al., “Determination of Drugs in Biosamples at Picomolar Concentrations Using Competitive Elisa With Electrochemical Detection: Application to Steroids”, Journal of Pharmaceutical and Biomedical Analysis, vo… [cited by applicant]
Lehar et al., “Novel antibody-antibiotic conjugate eliminates intracellular [cited by applicant]
Lemke et al., Foye's Principles of Medicinal Chemistry, Chapter 44, pp. 1253, Publication Year: 2008. [cited by applicant]
Lhospice et al. “Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models”, Mol. Pharmaceutics, 2015, vol. 12, pp. 1863-1871. [cited by applicant]
Lichtenecker R. J., “Synthesis of aromatic [cited by applicant]
Lim et al., “Targeted Delivery of LXR Agonist Using a Site-Specific Antibody-Drug Conjugate”, Bioconjugate Chemistry, 2015, vol. 26, No. 11, pp. 2216-2222. [cited by applicant]
Lu et al., “Linkers Having a Crucial Role in Antibody-Drug Conjugates”, Int. J. Mol. Sci., Apr. 14, 2016, vol. 17, No. 561, 22 pages. [cited by applicant]
Lyon et al., Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index, Nature Biotechnology, Jul. 2015, vol. 33, No. 7, pp. 733-735. [cited by applicant]
McCombs et al., “Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry”, The AAPS Journal, Mar. 2015, vol. 17, No. 2, pp. 339-351. [cited by applicant]
Miller-Larsson et al., “Reversible Fatty Acid Conjugation of Budesonide—Novel Mechanism for Prolonged Retention of Topically Applied Steroid in Airway Tissue”, Drug Metab. Dispos. 1998, vol. 26, pp. 623-630. [cited by applicant]
Mori et al., “Endocytic Pathway of Scavenger Receptors Via Trans-Golgi System In Bovine Alveolar Macrophages”, Laboratory Investigation, vol. 71, No. 3, 1994, pp. 409-417. [cited by applicant]
Muck et al., “High pressure liquid chromatography of some triamcinolone derivatives”, Bollettino chimico farmaceutica, Italy, Apr. 1981, 120(4), pp. 240-247; with an English abstract. [cited by applicant]
Papachristos et al., “Antibody-drug conjugates: a mini-review. The synopsis of two approved medicines”, Drug Delivery, 2016, vol. 23, No. 5, pp. 1662-1666; published online Jan. 27, 2015. [cited by applicant]
Park T. G., “Degradation of poly(lactic-co-glycolic acid) microspheres: effect of copolymer composition”, Biomaterials 16(15), 1995, pp. 1123-1130. [cited by applicant]
Paul-Clark et al., “Glucocorticoid Receptor Nitration Leads to Enhanced Anti-Inflammatory Effects of Novel Steroid Ligands”, The Journal of Immunology, 2003, vol. 171, pp. 3245-3252; doi: 10.4049/jimmunol.171.6.3245. [cited by applicant]
Peng, J., et al. “Chemoselective reduction of 21-azidocorticosteroids to primary 21-primary aminocorticosteroids.” Chemical Research In Chinese Universities (2004), 25(5), pp. 866-869. [cited by applicant]
Pufall (Adv Exp Med Biol. 2015; 872: 315-333). [cited by applicant]
Rabuka et al., “Site-specific chemical protein conjugation using genetically encoded aldehyde tags”, Nat Protoc., vol. 7, No. 6, pp. 1052-1067, Dec. 1, 2012, doi:10.1038/nprot.2012.04. [cited by applicant]
Reggelin et al., “Asymmetric Synthesis of Highly Substituted Azapolycyclic Compounds via 2-Alkenyl Sulfoximines: Potential Scaffolds for Peptide Mimetics”, J. American Chemical Society, Mar. 8, 2006, vol. 128, pp. 4023-… [cited by applicant]
Romero-Hernandez et al., “Diosgenin-based thio (seleno) ureas and triazolyl glycoconjugates as hybrid drugs. Antioxidant and antiproliferative profile”, European Journal Of Medicinal Chemistry, Editions Scientifique Els… [cited by applicant]
Romero-Hernández et al., “Diosgenin-based thio(seleno)ureas and triazolyl glycoconjugates as hybrid drugs, Antioxidant and antiproliferative profile”, European Journal of Medicinal Chemistry, May 14, 2015, vol. 99, pp. … [cited by applicant]
Ryan et al., “Polyclonal Antibody Production Against Chito-Oligosaccharides”, Food and Agricultural Immunology, 2001, vol. 13, pp. 127-130. [cited by applicant]
Sagar S. et al., Bifidobacterium breve and Lactobacillus rhamnosus treatment is as effective as budesonide at reducing inflammation in a murine model for chronic asthma, Respiratory Research, Apr. 16, 2014, vol. 15, No.… [cited by applicant]
Samal et al., “The First Synthesis of Water-Soluble Cyclodextrinazafullerenes”, Synthetic Communications, 2002, vol. 32, No. 21, pp. 3367-3372. [cited by applicant]
Samant et al., “Synthesis of 3-hydroxypyrid-2-ones from furfural for treatment against iron overload and iron deficiency”, European Journal Of Medicinal Chemistry, vol. 43, No. 9 , Sep. 1, 2008, pp. 1978-1982. [cited by applicant]
Sehgal et al., “Desoxymethasone: a new topical corticosteroid”, International Journal of Dermatology, Dec. 1976, vol. 15, pp. 770-773; with an English abstract. [cited by applicant]
Shaunak et al., “Site-specific PEGylation of native disulfide bonds in therapeutic proteins”, Nature Chemical Biology, Jun. 2006, vol. 2, No. 6, pp. 312-313. [cited by applicant]
Simons S. Jr. et al., “Alpha Keto Mesylate: a Reactive Thiol Specific Functional Group”, Journal of Organic Chemistry, American Chemical Society, Washington, vol. 45, No. 15, Jan. 1, 1980, pp. 3084-3088, XP008100022. [cited by applicant]
Singh et al., “Polymer Drug Conjugates: Recent Advancements in Various Diseases”, Current Pharmaceutical Design, May 10, 2016, vol. 22, No. 19, pp. 2821-2843, XP055490895. [cited by applicant]
Svendsen et al., “Antibody-Directed Glucocorticoid Targeting to CD163 M2-type Macrophages Attenuates Fructose-Induced Liver Inflammatory Changes”, Molecular Therapy—Methods & Clinical Develop, vol. 4, Mar. 2017, pp. 50-… [cited by applicant]
Tang et al., Org Biomol Chem 14:9501-9518, Oct. 28, 2016. [cited by applicant]
Taylor et al., “A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins”, Nucleic Acids Research, 1992, vol. 20, No. 23, pp. 6287-6295. [cited by applicant]
Thalen et al., “Epimers of budesonide and related corticosteroids. I. Preparative resolution by chromatography on Sephadex LH-20”, Acta Pharmaceutica Suecica, 1982, 19(4), pp. 247-266. [cited by applicant]
Thalen et al., “Synthesis and pharmacological properties of some 16α,17α-acetals of 16α hydroxyhydrocortisone, 16α-hydroxyprednisolone and fluorinated 16α-hydroxyprednisolones”, Acta Pharmaceutical Suecica, 1984, 21(2),… [cited by applicant]
Thalen, “Epimers of budesonide and related corticosteroids. II. Structure elucidation by mass spectrometry”, Acta Pharmaceutica Suecica, 1982, 19(5), pp. 327-354. [cited by applicant]
Tian et al., “Inhibition of influenza virus infection by multivalent pentacyclic triterpene-functionalized per-0-methylated cyclodextrin conjugates”, European Journal Of Medicinal Chemistry, Editions Scientifique Elsevi… [cited by applicant]
Toth et al., “Amino-derivatives of 11,17,21-Trihydroxy-3,20-Dioxo-1,4-Pregnadiene”, Nature 191, Aug. 5, 1961, p. 607. [cited by applicant]
Tumey et al., “ADME Considerations for the Development of Biopharmaceutical Conjugates Using Cleavable Linkers”, Current Topics In Medicinal Chemistry, vol. 17, No. 32, 2017, pp. 3444-3462. [cited by applicant]
Tunek et al., “Reversible Formation of Fatty Acid Esters of Budesonide, an Antiasthma Glucgcorticoid, In Human Lung and Liver Microsomes”, Drug Metab. Dispos. 1997, vol. 25, No. 11, pp. 1311-1317. [cited by applicant]
Uekama et al., “6 [cited by applicant]
Uhrich et al., “Polymeric Systems for Controlled Drug Release”, Chemical Reviews, 1999, vol. 11, pp. 3181-3198. [cited by applicant]
Vert et al., “Something new in the field of PLA/GA bioresorbable polymers?” Journal of Controlled Release 53, 1998, pp. 85-92. [cited by applicant]
Wang et al., “Bioconjugation by Copper(I)-Catalyzed Azide-Alkyne [3+2] Cycloaddition”, J. Am. Chem. Soc., 2003, vol. 125, pp. 3192-3193. [cited by applicant]
Wikby et al., “Separation of epimers of budesonide and related corticosteroids by high-performance liquid chromatography. A comparison between straight- and reversed-phase systems”, Journal of Chromatography, 1978, 157(… [cited by applicant]
Wikby et al., “Separation of epimers of budesonide and related corticosteroids by reversed bonded-phase liquid chromatography”, Journal of Chromatography, 1978, 157(1), pp. 51-64. [cited by applicant]
Williams et al., (Foye's Principles of Medicinal Chemistry, 5th Ed, pp. 59-63, 2002. [cited by applicant]
Xiao et al., “Synthesis and biological evaluation of novel pentacyclic triterpene [alpha]-cyclodextrin conjugates as HCV entry inhibitors”, European Journal Of Medicinal Chemistry, Nov. 1, 2016, vol. 124, pp. 1-9, XP055… [cited by applicant]
Yano et al., “Preparation of prednisolone-appended [alpha]-, [beta]- and [gamma]-cyclodextrins: Substitution at secondary hydroxyl groups and in vitro hydrolysis behavior”, Journal of Pharmaceutical Sciences, American C… [cited by applicant]
Zoltan, T., et al. “Synthesis of biologically active amino and aza steroids and some of their new chemical reactions”, Int. Conf. Chem. Biotechnol. Biol. Act. Nat. Prod., 1981, 2, pp. 135-149. [cited by applicant]
“European Application Serial No. 18729847.6, Communication Pursuant to Article 94(3) EPC mailed Apr. 10, 2025”, 4 pgs. [cited by applicant]
“Indian Application Serial No. 201917047055, First Examination Report mailed Jun. 30, 2025”, 7 pgs. [cited by applicant]
“Australian Application Serial No. 2024205046, First Examination Report mailed Aug. 5, 2025”, 5 pgs. [cited by applicant]